The good news for Daiichi Sankyo: Its new anticoagulant drug matched the old standard-issue drug warfarin at preventing stroke and blood clots. And as far as safety goes, edoxaban beat warfarin by a significant stretch. That's an entree into the warfarin-alternative market, expected to grow to $10 billion over the next several years.
According to an EP Vantage report, analysts' predictions for 2014 sales of the anticoagulant have fallen 60% in the last 12 months. They now stand at $491 million. That is as projections for 2014 sales of Xarelto have surged by 81% and 60% in the respective territories for J&J and Bayer, to $1 billion and $1.4 billion.
Every drugmaker dreams of developing a drug so important that it shakes up an entire market. And it happens--just think of Johnson & Johnson's Zytiga, the prostate cancer drug that has not only grown by leaps and bounds, but arguably nudged aside Dendreon's competing treatment, Provenge. Want new examples? That's what Motley Fool offers today.
As goes Eliquis, so goes Bristol-Myers Squibb. That's true this quarter anyway, with the company cutting its full-year revenue and earnings forecasts at the same time it announces remarkably weak sales of its new anticoagulant drug.
China has fast become a huge pillar on the global R&D scene, with local CROs like WuXi PharmaTech and ShangPharma cashing in on demand for clinical trials in the country. But, with the FDA chiding a sloppy Chinese trial run by Bristol-Myers Squibb, Pfizer and PPD, regulators and researchers may think twice before accepting data gathered in the country.
The FDA will consider Eliquis for a new indication, one which Pfizer and partner Bristol-Myers Squibb hope can help the blood thinner hit the sales potential analysts predicted for the drug before it was approved.
The allegations could raise more questions about the integrity of drug research in China.
Nearly 7 months since the FDA approved the blockbuster candidate Eliquis, media reports have shed light on data errors and a case of alleged fraud from clinical trial sites in China. The revelations in reports from Elsevier and Bloomberg could further harm the image of China as a hotspot for clinical development.
Pfizer and Bristol-Myers Squibb announced today that their anticoagulant drug Eliquis matched standard treatment for potentially life-threatening blood clots, efficacy-wise. And it beat warfarin on the safety side, with a 69% reduction in the risk of major bleeding.
Pfizer believes it has a winner with Eliquis. It has the right market niche, a replacement for blood thinner warfarin, and the clinical data that should make it a star. What it hasn't had so far is a fast start toward bigtime sales.